Application Nr Approved Date Route Status External Links
ANDA210945 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Deferasirox Tablets Are An Iron Chelator Indicated For The Treatment Of Chronic Iron Overload Due To Blood Transfusions In Patients 2 Years Of Age And Older. ( 1.1 ) Limitations Of Use The Safety And Efficacy Of Deferasirox Tablets When Administered With Other Iron Chelation Therapy Have Not Been Established. ( 1.3 ) 1.1 Treatment Of Chronic Iron Overload Due To Blood Transfusions (transfusional Iron Overload) Deferasirox Tablets Are Indicated For The Treatment Of Chronic Iron Overload Due To Blood Transfusions (transfusional Hemosiderosis) In Patients 2 Years Of Age And Older. Additional Pediatric Use Information Is Approved For Novartis Pharmaceuticals Corporation’s Jadenu ® (deferasirox) Tablets. However, Due To Novartis Pharmaceuticals Corporation’s Marketing Exclusivity Rights, This Drug Product Is Not Labeled With That Pediatric Information. 1.3 Limitations Of Use The Safety And Efficacy Of Deferasirox Tablets When Administered With Other Iron Chelation Therapy Have Not Been Established.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Deferasirox DEFERASIROX ZINC1481815

Comments